6:30 AM Registration and Breakfast
7:00 AM Welcome and Overview
7:05 AM Small Molecule Inhibitor Landscape in Mature B-Cell Lymphomas: Current Status, Future Directions, and Clinical Considerations
7:30 AM Pharmacist Focus on Integrating CAR T-Cell Therapy Into the Management of Mature B-Cell Lymphoma
7:55 AM Final Thoughts and Audience Q & A Session
Date / Time
Anthony Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
Clinical Team Leader, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan
Zahra Mahmoudjafari, PharmD, BCOP, DPLA
Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate novel therapies (including BTK and PI3K inhibitors, next-generation antibodies, BCL-2 inhibitors, CAR T-cell, investigational agents, and immunotherapeutic strategies currently under evaluation) and recent findings into the treatment of patients with mature B-cell NHLs.
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with B-cell malignancies.
Upon completion of this activity, participants should be able to:
- Consider efficacy and safety profile of the novel classes of therapies (including BTK and PI3K inhibitors, antibodies, BCL-2 inhibitors, CAR T-cell, investigational agents, and immunotherapeutic strategies currently under evaluation) with patient characteristics and molecular features to individualize therapeutic strategies for patients with mature B-cell lymphomas
- Consider mechanisms of action and efficacy and safety profile differences among different agents in the same class of therapy to select treatments most likely to improve outcomes
- Assess challenging questions regarding the use of novel therapies in mature B-cell lymphomas and discuss the ways that pharmacists can optimize therapy, anticipate adverse effects, and optimize clinical outcomes alongside other members of the oncology healthcare team
- Manage unique adverse events associated with novel agent classes in the management of mature B-cell lymphomas to optimize care and quality of life
- Identify patients suitable for enrollment on ongoing clinical studies investigating novel therapies in mature B-cell lymphomas
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Satellite Universal Activity Number - JA4008176-0000-20-028-L01-P
Simulcast Universal Activity Number - JA4008176-0000-20-029-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.